Adam Feuerstein

When people talk Gilead Sciences, Inc. (NASDAQ: GILD) takeover possibilities, TESARO Inc (NASDAQ: TSRO) and Incyte Corporation (NASDAQ: INCY) commonly surface. But biotech reporter Adam Feuerstein posited a less conventional interest — orphan-drug company BioMarin Pharmaceutical Inc. (NASDAQ...

Following his Tuesday tweets regarding Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)’s stock pumping, TheStreet's Adam Feuerstein told Benzinga the instance is only one example of an enduring problem in the market. “This company is one of the worst biotech companies out there that has...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) were trading lower by around 10 percent Thursday morning, even though the company reported positive, top-line data from an ongoing clinical trial. Corbus has been exploring its Anabasum (Resunab) therapy in a Phase 2 study for the...

Shares of Amgen, Inc. (NASDAQ: AMGN) fell 7 percent after the biotechnology company released data from its therapy called Repatha, which is used to lower the risk of heart attacks, strokes and heart problems. Amgen reported Repatha reduces the risk of heart attacks, stokes and other heart-related...

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are down more than 20 percent Tuesday after nearly tripling in a month’s time. For traders wondering how the stock lost its mojo, the Twitter feed of TheStreet columnist Adam Feuerstein tells the story. Related Link: 7 Tweets That Ruined...

The pharmaceutical industry, rich with innovative players and shaken by impending regulatory changes, is a well-worn topic on Wall Street. Adam Feuerstein joined Benzinga’s Pre-Market Prep radio show to comment on the status of the market and recent activity in the sphere. Will Novogen-GBT...

There’s a lot of ambiguity surrounding the GOP healthcare strategy — enough to render market predictions nearly impossible. In an interview on Benzinga's PreMarket Prep Friday morning, Adam Feuerstein, the biotech reporter at TheStreet, noted that estimates are particularly muddied...

Trevena Inc (NASDAQ: TRVN), a clinical-stage biopharmaceutical company that focuses on therapeutics that use an approach to target G protein coupled receptors (GPCRs), saw its shares plummet around 30 percent Tuesday morning despite a positive development in Phase 3 trials. Trevena announced...

The tricky thing about pharmaceuticals is that, in theory, they’re meant to write themselves out of the equation. True success — a world without disease — would also mean a world without drugs and a world without pharmaceuticals. When drug companies are successful, they cease to...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) jumped nearly 10 percent early Friday morning after the company provided an update on an ongoing clinical trial. Intercept is a biopharmaceutical company that focuses on developing and commercializing therapeutics to treat progressive non-viral...

Shares of Galena Biopharma Inc (NASDAQ: GALE) are up nearly 50 percent Monday after the company announced the results from a Data Safety Monitoring Board (DSMB) meeting related to two investigator-sponsored (IST) combination clinical trials of NeuVax with trastuzumab. According to the press...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher by more than 24 percent Tuesday. The catalyst for the move appears to be the company's 10:30 a.m. presentation at the JPMorgan Healthcare Conference, followed by an encouraging report by TheStreet's Adam Feuerstein. As...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares are trading higher by $1.31 at $12.00 in Thursday's session. The issue spiked to $17.045 in pre-market trading but has come nowhere near that level during the regular session. The catalyst for the brief rally was the announcement that a Phase 2...

Professional investors spend over $600 million per year speaking with the most qualified experts before risking their capital. Until now, this information was unavailable to most investors. But Slingshot Insights is trying to change that by offering every investor access to the same insiders...